Qianmiao Gao

Qianmiao Gao

Auto-generated profile, based on publicly available information

Qianmiao Gao

Division of Biostatistics, Office of Biostatistics and Pharmacovigilance, CBER, FDA, Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in The Ocular Surface
Verified
Journal Article
Closed access
DLDe-Quan Li
De-Quan Li
SKSangbae Kim
Sangbae Kim
JLJin-Miao Li
Jin-Miao Li
QGQianmiao Gao
Qianmiao Gao
JCJongsu Choi
Jongsu Choi
Rui ChenRui Chen
Rui Chen

23 July 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
LHLianne Hu
Lianne Hu
CFChaohong Fan
Chaohong Fan
PBPeter Bross
Peter Bross
ADAsha Das
Asha Das
ECElin S. Cho
Elin S. Cho
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
On February 16, 2024, the FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1–blocking antibody and, if BRAF V600 mutation positive, a BRAF inhibitor with or without an MEK inhibitor. Lifileucel is the first tumor-derived T-cell therapy approved by the FDA. In the phase II single-arm trial, Study C-144-01, that served as the basis for approval, the objective response rate among patients treated with lifileucel within FDA-approved dose range (7.5 × 109 to 72 × 109 viable cells, n = 73) in the primary efficacy cohort was 31.5% (95% confidence interval, 21.1%–43.4%), including three (4.1%) complete responses and 20 (27.4%) partial responses. The median duration of response was not reached (95% confidence interval, 4.1 months–not reached). Among the responders (n = 23), 56.5%, 47.8%, and 43.5% maintained durable responses at 6, 9, and 12 months, respectively. Among all patients who received lifileucel (n = 156) in the primary and supportive cohorts of Study C-144-01, 95.5% of patients experienced at least one Grade 3 treatment-emergent adverse event and 87.8% experienced at least one Grade 4 treatment-emergent adverse event. Lifileucel labeling includes a Boxed Warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary impairment, and renal impairment.

15 July 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
KBKristen Britton
Kristen Britton
UMUpendra Mahat
Upendra Mahat
NRNicholas C. Richardson
Nicholas C. Richardson
MTMillion Adane Tegenge
Million Adane Tegenge
QGQianmiao Gao
Qianmiao Gao
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
In May 2024, the FDA granted accelerated approval to lisocabtagene maraleucel for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. The single-arm, open-label, multicenter, phase 2 TRANSCEND-FL trial evaluating a single dose of lisocabtagene maraleucel in adults with R/R indolent non-Hodgkin lymphoma supported the FL indication. The trial enrolled 139 patients with R/R FL, including 107 with two or more prior lines of therapy. Of the 107 patients, 94 patients comprised the primary efficacy population and the independent review committee-assessed overall response rate was 95.7% (95% confidence interval [CI]: 89.5, 98.8), with 73.4% (95% CI: 63.3, 82.0) achieving complete response. The median duration of response was not reached (95% CI: 18.0 months, NR) and the 1-year remission rate was 81% (95% CI: 71, 88). Serious adverse reactions occurred in 26% of patients, most often due to cytokine release syndrome (CRS), neurologic toxicity, and febrile neutropenia. CRS occurred in 59% (Grade 3: 1%) of patients and neurologic toxicities occurred in 15% (Grade 3: 2%). As a condition of accelerated approval, post marketing studies were required to verify the clinical benefit of lisocabtagene maraleucel in R/R FL. This article summarizes key aspects of the regulatory review.